mynth
← DATABASE
09/2026100%

Katalyst Diagnostics acquired by Cruinn Diagnostics

UNITED KINGDOM B2B Specialized Distribution REV 1m EUR - 100m EUR

Context

Announced on September 24, 2026, Cruinn Diagnostics’ acquisition of Katalyst Diagnostics brings together two complementary distribution specialists to build an integrated healthcare platform generating €50M in annual sales. The cross-border deal represents the first step in Cruinn’s buy-and-build strategy in the UK, aimed at scaling combined revenue toward €150 million. Backed by a team of over 100 employees across regional hubs, Katalyst will retain its current leadership team, with CEO Afsheen Khan continuing to direct UK operations. Cruinn CEO Peter Hussey framed the move as an entry point into Britain, connecting Katalyst’s established NHS relationships, sales network, and point-of-care portfolio with Cruinn’s core laboratory diagnostic and calibration services. Looking ahead, Cruinn plans to leverage this expanded footprint to pursue targeted add-on acquisitions across continental Europe.

Katalyst Diagnostics, which reported an EBITDA margin of [members only] in 2026, is valued in this transaction at an EV/EBITDA multiple of [members only].

-> Deep-dive in Business Services market trends

Target

Headquartered in the UK, Katalyst Diagnostics supplies point-of-care testing technologies, specialized diagnostic instrumentation, and clinical support across the British healthcare sector. The company partners directly with NHS hospital trusts as well as private and specialized medical facilities nationwide. Its portfolio centers on decentralized diagnostic devices built for fast, targeted use across key specialties, including psychiatry, oncology, pediatrics, and emergency care. Led by CEO Afsheen Khan, Katalyst combines product distribution with dedicated account management and hands-on clinical support tailored to the daily demands of healthcare providers.

Ent. Value

[members only]

Equity Value

[members only]

Multiples

EV / Revenue

[members only]

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2026
€1–100M
[members only]
[members only]
2025
€1–100M
[members only]
[members only]

Similar deals in B2B Specialized Distribution

Similar deals in B2B Specialized Distribution
DateAcquirerTargetCountrySector
10/2026WATERLANDTERR ASIAFRANCEB2B Specialized Distribution
10/2026KITWAVE GROUPFIRST CHOICE FOODSERVICEUNITED KINGDOMB2B Specialized Distribution
09/2026C&C GROUPNECTAR IMPORTSUNITED KINGDOMB2B Specialized Distribution
09/2026AGRI EXOTIC TRADINGMELLONE WHOLESALE PRODUCEUNITED STATESB2B Specialized Distribution
07/2026H2 EQUITY PARTNERSLYNCH MEDICAL SUPPLIESIRELANDHospitality Supplies
07/2026KITWAVE GROUPFIFE CREAMERYUNITED KINGDOMB2B Specialized Distribution
07/2026KITWAVE GROUPCHARLES SAUNDERSUNITED KINGDOMHospitality Supplies
06/2026CREDIT MUTUEL EQUITYONELECFRANCEB2B Specialized Distribution
04/2026FASSI GROUPFASCAN INTERNATIONALUNITED STATESB2B Specialized Distribution
03/2026BAIN CAPITALTINGSTADSWEDENHospitality Supplies

REFERENCES

Revenue range: REV 1m EUR - 100m EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Katalyst Diagnostics by Cruinn Diagnostics are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: katalyst diagnostics

FAQ

What transaction does this page cover?

This page covers Cruinn Diagnostics’s acquisition of 100% of Katalyst Diagnostics, a British company specialised in B2B Specialized Distribution, in 2026.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.